Magnetic resonance imaging plays a key role in diagnosis and treatment monitoring of brain
tumors. Novel imaging techniques that specifically interrogate aspects of underlying tumor …

Background The majority of WHO grades II and III gliomas harbor a missense mutation in the
metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2 …

Despite intensive research, brain tumors are amongst the malignancies with the worst
prognosis; therefore, a prompt diagnosis and thoughtful assessment of the disease is …

2-Hydroxyglutarate (2-HG) is a potential oncometabolite involved in gliomagenesis that has
been identified as an aberrant product of isocitrate dehydrogenase (IDH)–mutated glial …

The implementation of advanced MRS methods in the routine clinical practice will allow the
quantification of metabolites that are not detectable with conventional methods and may …

Purpose Proton magnetic resonance spectroscopy (MRS) of the brain can detect 2-
hydroxyglutarate (2HG), the oncometabolite produced in neoplasms harboring a mutation in …

Background The alternative lengthening of telomeres (ALT) pathway is essential for tumor
proliferation in astrocytomas. The goal of this study was to identify metabolic alterations …

Background Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-
hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the …

Simple Summary IDH mutation is one of the most important prognostic biomarkers in glioma
management. Noninvasive neuroimaging techniques to predict IDH mutant glioma may be …

The reprogramming of cellular metabolism is a hallmark of cancer diagnosis and prognosis.
Proton magnetic resonance spectroscopic imaging (MRSI) is a non-invasive diagnostic …